VT30 ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 278 | Huge lymphatic malformation with cervicofacial lesion | 1 |
| 279 | Huge venous malformation with cervical, oral and pharyngeal diffuse lesion | 1 |
278. Huge lymphatic malformation with cervicofacial lesion
Clinical trials : 22 / Drugs : 27 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04409145 (ClinicalTrials.gov) | October 1, 2020 | 11/5/2020 | First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations | Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations | Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation | Drug: VT30 | Venthera, Inc., a BridgeBio company | NULL | Recruiting | 18 Years | 60 Years | All | 51 | Phase 1/Phase 2 | United States |
279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion
Clinical trials : 14 / Drugs : 24 - (DrugBank : 9) / Drug target genes : 3 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04409145 (ClinicalTrials.gov) | October 1, 2020 | 11/5/2020 | First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations | Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations | Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation | Drug: VT30 | Venthera, Inc., a BridgeBio company | NULL | Recruiting | 18 Years | 60 Years | All | 51 | Phase 1/Phase 2 | United States |